Medical Device Company Argues For Denial Of U.S. High Court Review Of Patent
(May 12, 2016, 1:54 PM EDT) -- WASHINGTON, D.C. — A global pharmaceutical and medical device company argues in an April 17 brief that the Federal Circuit U.S. Court of Appeals properly followed legal precedent in affirming a district court’s ruling that asserted that claims of four patents for an antibiotic were obvious and, thus, invalid (Cubist Pharmaceuticals, Inc. v. Hospira, Inc., No. 15-1210, U.S. Sup.).
(Respondent’s opposition brief available. Document #78-160516-001B.)
Relying on the post-trial factual findings of a Delaware federal judge, the Federal Circuit on Nov. 12 upheld findings that four...